Send to

Choose Destination
Indian J Cancer. 2020 Jan-Mar;57(1):13-17. doi: 10.4103/ijc.IJC_614_18.

Efficacy and safety of apatinib monotherapy in elderly patients with advanced metastatic non-small cell lung cancer.

Author information

Department of Cardiothoracic Surgery, Huanggang Central Hospital, Huanggang, Hubei, China.
Department of Oncology, The First People's Hospital of Jingzhou, Jingzhou, China.



No effective and definitive chemotherapeutic regimen has been established in patients with non-small cell lung cancer (NSCLC) who failed second-line treatment. The aim of this study was to evaluate apatinib, a VEGFR-2 inhibitor, as monotherapy in elderly patients with advanced metastatic NSCLC.


We evaluated the efficacy and safety of apatinib in elderly patients (≥65 years old) with advanced metastatic NSCLC who failed second-line treatment from 2015 to 2016 in Huanggang Central Hospital. Survival analysis was performed by the Kaplan-Meier method. Toxicities were evaluated according to the National Cancer Institute Common Toxicity Criteria version 4.0.


Twenty patients were included in the present study. Two patients achieved partial response, and 9 achieved stable disease, representing a response rate of 10% and a disease control rate of 55%. Median progression-free survival and overall survival were 2.8 and 6.0 months, respectively. The toxicities associated with apatinib were generally acceptable with a total grade 3/4 toxicity of 50%.


Apatinib is an optional choice as salvage treatment in elderly patients with advanced metastatic NSCLC, with modest efficacy and acceptable toxicities.


Antiangiogenic agents; apatinib; elderly patients; non-small cell lung cancer; targeted therapy

Free full text

Supplemental Content

Full text links

Icon for Medknow Publications and Media Pvt Ltd
Loading ...
Support Center